Summary
Despite neoadjuvant treatment being available for esophageal cancer, surgery remains the cornerstone of treatment. The aim of this article is to give a clear and simple overview of current issues in the available surgical strategies relating to locally limited and advanced disease, including the following: clinical staging, preoperative general condition and comorbidities, surgical strategy, surgical approaches, postoperative complications and the role of surgery in advanced disease. Based on a literature search and our personal professional experience to date, enhanced surgical treatment protocols for the treatment of the adenocarcinomas of esophagogastric junction (AEG) and the squamous cell carcinoma of the esophagus are presented and discussed. Eligibility for a surgical resection strongly depends on the stage of the tumor and on the comorbidities. A minimally invasive laparoscopic approach should be preferred in the case of limited disease, regardless of its histology, or limited/advanced intrathoracic squamous cell carcinoma (hybrid technique: laparoscopic approach combined with thoracotomy). The surgical strategy in the case of adenocarcinoma to achieve radical resection depends on the tumor location. Finally, surgery should be performed by a multidisciplinary team that includes medical oncologists, radiation oncologists, gastroenterologists, dieticians and physiotherapists, so as to minimize the postoperative complications rates and improve early postoperative outcomes and overall patient survival. Therefore, we support the centralization of treatment of esophageal cancer to high volume centers.
Similar content being viewed by others
References
Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390:2383–96.
Borggreve AS, Kingma BF, Domrachev SA, Koshkin MA, Ruurda JP, van Hillegersberg R, Takeda FR, Goense L. Surgical treatment of esophageal cancer in the era of multimodality management. Ann N Y Acad Sci. 2018; https://doi.org/10.1111/nyas.13677.
Kassis ES, Kosinski AS, Ross P, et al. Predictors of anastomotic leak after esophagectomy: an analysis of the society of thoracic surgeons general thoracic database. Ann Thorac Surg. 2013;96:1919–26.
Kechagias A, van Rossum PSN, Ruurda JP, van Hillegersberg R. Ischemic conditioning of the stomach in the prevention of esophagogastric anastomotic leakage after esophagectomy. Ann Thorac Surg. 2016;101:1614–23.
Goense L, van Rossum PSN, Kandioler D, et al. Stage-directed individualized therapy in esophageal cancer. Ann N Y Acad Sci. 2016;1381:50–65.
Findlay JM, Bradley KM, Maile EJ, et al. Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy. Br J Surg. 2015;102:1488–99.
Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl. 5):v50–v7.
van der Horst S, van Hillegersberg R. Esophagectomy for patients with esophageal cancer and cervical lymph node metastases (node). 2015. https://clinicaltrials.gov/ct2/show/NCT02426879. Accessed 5 Feb 2018.
Li S‑J, Wang Z‑Q, Li Y‑J, et al. Diabetes mellitus and risk of anastomotic leakage after esophagectomy: a systematic review and meta-analysis. Dis Esophagus. 2017;30:1–12.
Nienhueser H, Kunzmann R, Sisic L, et al. Surgery of gastric cancer and esophageal cancer: does age matter? J Surg Oncol. 2015;112:387–95.
Wei R, Dong W, Shen H, et al. Predictive effects of lung function test on postoperative pneumonia in squamous esophageal cancer. Sci Rep. 2016;6:23636.
van Adrichem EJ, Meulenbroek RL, Plukker JTM, et al. Comparison of two preoperative inspiratory muscle training programs to prevent pulmonary complications in patients undergoing esophagectomy: a randomized controlled pilot study. Ann Surg Oncol. 2014;21:2353–60.
Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–8.
Al-Batran SE, Pauligk C, Homann N, Schmalenberg H, Kopp HG, Haag GM, Luley KB, Schmiegel Wolff H, Folprecht G, Probst S, Prasnikar N, Thuss-Patience PC, Trojan J, Goetze TO, Meiler J, Schuler MH, Jäger E, Hofheinz RD. LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Group at AIO). Ann Oncol. 2017; https://doi.org/10.1093/annonc/mdx302.007.
Haverkamp L, Seesing MF, Ruurda JP, et al. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer. Dis Esophagus. 2017;30:1–7.
Glatz T, Marjanovic G, Kulemann B, et al. Hybrid minimally invasive esophagectomy vs. open esophagectomy: a matched case analysis in 120 patients. Langenbecks Arch Surg. 2017;402:323–31.
Rinieri P, Ouattara M, Brioude G, et al. Longterm outcome of open versus hybrid minimally invasive Ivor Lewis oesophagectomy: a propensity score matched studydagger. Eur J Cardiothorac Surg. 2017;51:223–9.
Briez N, Piessen G, Bonnetain F, et al. Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial—the MIRO trial. BMC Cancer. 2011;11:310.
American Society of Clinical Oncology. ESMO 2017: MIRO trial: 3‑year outcomes favor laparoscopic surgery for esophageal cancer. 2017. http://www.ascopost.com/News/58020. Accessed 15 Dec 2017.
Markar S, Gronnier C, Duhamel A, et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol. 2015;33:3866–73.
Brusselaers N, Mattsson F, Lagergren J. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut. 2014;63:1393–400.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
P.N.C. Girotti and I. Königsrainer declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Girotti, P.N.C., Königsrainer, I. Surgical concepts in esophageal cancer. memo 12, 46–50 (2019). https://doi.org/10.1007/s12254-018-0467-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-018-0467-0